Stifel on Alkermes (ALKS): 'big picture we still think orexins have real potential in ADHD'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $63.00 price target on Alkermes (NASDAQ: ALKS).The analyst comments "We are ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




